Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 22;57:102834. doi: 10.1016/j.ebiom.2020.102834

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig 1 — Salivary Lf levels by clinical diagnosis and amyloid-PET biomarker profile. Box and whisker plots showing salivary Lf levels across diagnostic groups within (a) cohort 1, and (b) cohort 2. Boxes represent the 25th, 50th and 75th data percentiles. Whiskers represent the lowest and highest data. Scatter plots showing salivary Lf levels in (c) all subjects grouped as negative (n = 165) and positive (n = 85) amyloid-PET biomarker profile (excluding the control-PET⁺ subjects), and (d) in patients (excluding healthy asymptomatic controls) grouped as negative (n = 47) and positive (n = 85) amyloid-PET biomarker profile. Differences between groups were assessed using Kruskal-Wallis test or one-way ANOVA followed by Bonferroni and Student's t-test. *p < 0•05; ****p < 0•0001. Lf, lactoferrin; MCI, Mild cognitive impairment; AD, Alzheimer´s disease dementia; FTD, frontotemporal dementia; PET⁺, positive amyloid-PET scan; PET⁻, negative amyloid-PET scan.